Dublin, March 14, 2019 (GLOBE NEWSWIRE) -- The "Global Colorectal Cancer Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The colorectal cancer therapeutics market will register a CAGR of almost 3% by 2023.

The global colorectal cancer therapeutics market is largely dominated by monotherapy drugs, including targeted therapies and immunotherapies. However, the combination of these monotherapy drugs with chemotherapy or other therapeutics also increases the therapeutic value.

The combination of drugs helps in overcoming the limitations of each therapeutic and increases the overall outcome in the treatment of colorectal cancer. Furthermore, the combination of therapies with or without surgery can be used to reduce the spreading of the disease and temporarily shrink a cancerous tumor.

Moreover, the combination therapy that contains two or more number of therapeutics is useful to achieve an additive or synergistic effect with low doses of combinational therapeutics.

Rising population with risk factors of colorectal cancer

The incidence of colorectal cancer is increasing owing to the risk factors such as the increasing geriatric population, inflammatory diseases, genetic syndromes, and changes in lifestyle. Hence, an increase in the number of patients with these risk factors is expected to increase the development of colorectal cancer.

This, in turn, is expected to aid in the use of available therapeutics, which will drive the growth of the global colorectal cancer therapeutics market during the forecast period.

Patent expiration of novel therapeutics

The pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. The expiration of patents and other intellectual property rights of therapeutics are likely to hamper the growth of the global colorectal cancer therapeutics market during the forecast period.

Competitive Landscape

The market appears to be fairly concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry

PART 06: MARKET SEGMENTATION BY TYPE

• Comparison by type
• Targeted therapy - Market size and forecast 2018-2023
• Immunotherapy - Market size and forecast 2018-2023
• Chemotherapy - Market size and forecast 2018-2023
• Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

• Overview
• Landscape disruption
• Competitive scenario

PART 13: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/7q8dxq/worldwide?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Colon Cancer Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.